Abstract
Disease caused by cytomegalovirus (CMV) infection can clinically manifest in a variety of ways in the immunodeficient host and lead to significant morbidity and mortality. Infections can be primary, occur as a result of reactivation of latent virus, or infection with a new strain of CMV. Cell-mediated immunity is the main defense against CMV disease. This component of the immune system is frequently affected in children who are born prematurely, have undergone solid organ transplantation or hematopoietic stem cell transplantation, or have infection with human immunodeficiency virus. Accordingly, these children are at increased risk for severe disease due to CMV. In addition, CMV itself alters cell-mediated immunity and may predispose hosts to other bacterial, fungal, or viral infections as well as predispose to graft rejection. The importance of CMV in these special populations of children, emphasizing epidemiology, risk factors, and preventive strategies, is reviewed.
Keywords: Cytomegalovirus, immunocompromised hosts, immunosuppressed, infections, prematurity, transplant, opportunistic, latent virus, stem cell transplantation, seroprevalence, socioeconomic status, symptomatic, suppressor cytotoxic T cells, combining culture
Infectious Disorders - Drug Targets
Title: Cytomegalovirus Infection in Pediatric Immunocompromised Hosts
Volume: 11 Issue: 5
Author(s): Marsha Y. Russell, April Palmer and Marian G. Michaels
Affiliation:
Keywords: Cytomegalovirus, immunocompromised hosts, immunosuppressed, infections, prematurity, transplant, opportunistic, latent virus, stem cell transplantation, seroprevalence, socioeconomic status, symptomatic, suppressor cytotoxic T cells, combining culture
Abstract: Disease caused by cytomegalovirus (CMV) infection can clinically manifest in a variety of ways in the immunodeficient host and lead to significant morbidity and mortality. Infections can be primary, occur as a result of reactivation of latent virus, or infection with a new strain of CMV. Cell-mediated immunity is the main defense against CMV disease. This component of the immune system is frequently affected in children who are born prematurely, have undergone solid organ transplantation or hematopoietic stem cell transplantation, or have infection with human immunodeficiency virus. Accordingly, these children are at increased risk for severe disease due to CMV. In addition, CMV itself alters cell-mediated immunity and may predispose hosts to other bacterial, fungal, or viral infections as well as predispose to graft rejection. The importance of CMV in these special populations of children, emphasizing epidemiology, risk factors, and preventive strategies, is reviewed.
Export Options
About this article
Cite this article as:
Y. Russell Marsha, Palmer April and G. Michaels Marian, Cytomegalovirus Infection in Pediatric Immunocompromised Hosts, Infectious Disorders - Drug Targets 2011; 11 (5) . https://dx.doi.org/10.2174/187152611797636686
DOI https://dx.doi.org/10.2174/187152611797636686 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point
Anti-Cancer Agents in Medicinal Chemistry The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature
Cardiovascular & Hematological Agents in Medicinal Chemistry Carcinogenesis and Therapeutic Strategies in Thyroid Cancer
Current Drug Targets Editorial (Another Year of Prosperity for Current Molecular Medicine)
Current Molecular Medicine The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib
Current Drug Targets Editorial [Hot Topic: Recombinant Immunotoxins – The Next Generation (Executive Editor: Stefan Barth)]
Current Pharmaceutical Design Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis
Current Cancer Therapy Reviews Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Curcumin Targets Circulating Cancer Stem Cells by Inhibiting Self-Renewal Efficacy in Non-Small Cell Lung Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Drug-Induced Mitotic Catastrophe in Cancer Cells
Current Pharmaceutical Design Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data
Current Drug Safety MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis
Current Genomics Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters